• Granite Creek Senior Advisor Dhani Jones interviewed Royal Biologics CEO Salvatore Leo on scaling a founder-led medical device company.
• Leo flagged a key inflection point in growth: delegating operational control to trusted hires to remove founder bandwidth constraints.
• He described the most difficult scaling phase as deliberate over-investment that can depress EBITDA for 12 to 24 months before payoffs emerge.
• Leo said Granite Creek stood out by pushing longer planning horizons of 12, 24, 36 months, including earlier infrastructure buildouts.
• He said signing delivered added resources and a board-level sounding board, alongside heightened execution risk for management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Granite Creek Capital Partners LLC published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.